Vitrisa Therapeutics, Inc.

Albert Einstein College of Medicine

396419 B.c. Ltd.

Carl Erickson

Christopher P Rusconi

Kevin G McLure

Matthew Levy

Arijit Bhowmick

Renta Hutabarat

The application discloses methods and compositions for the inhibition of the alternative complement pathway. The methods and compositions involve the use of aptamers for inhibiting complement Factor D. The application further provides anti-Factor D aptamers for the treatment of dry age-related macular degeneration, geographic atrophy, wet age-related macular degeneration or Stargardt disease. In some cases, stem-loop aptamers are provided for the inhibition of Factor D.

Stem-loop compositions and methods for inhibiting factor D

The application discloses methods and compositions for the inhibition of the alternative complement pathway. The methods and compositions involve the use of aptamers for inhibiting complement Factor D. The application further provides anti-Factor D aptamers for the treatment of dry age-related macular degeneration, geographic atrophy, wet age-related macular degeneration or Stargardt disease.

Compositions and methods for inhibiting factor D

Provided herein are compositions and methods for the treatment of retinal diseases. The compositions and methods include a therapeutic agent conjugated to a vitreous component binding moiety. The vitreous component binding moiety may be an aptamer or a small molecule that binds to a structural component of the vitreous humor (e.g., hyaluronic acid, collagen or vitronectin).

Compositions with improved intravitreal half-life and uses thereof

Compositions and methods for inhibiting Factor D

Growing community of inventors

Corte Madera, CA, United States of America

Carl Erickson